Allergan's Ulipristal, Dogged By Liver Concerns, Gets An FDA Rejection
US FDA issued a complete response letter for ulipristal acetate for the treatment of bleeding in women with uterine fibroids. The action wasn't unanticipated, but a disappointment nonetheless while Allergan tries to sell its women's health unit.
You may also be interested in...
Allergan was expected to announce soon that it would follow its shareholders' advice and split the company in two, but it's being acquired by AbbVie for $63bn instead, finally giving investors a big boost in their Allergan holdings after years of decline.
Relugolix meets primary and six key secondary endpoints in first Phase III UF study. Magnitude of benefit for primary endpoint does not equal AbbVie’s elagolix, but Myovant thinks it will offer safety, tolerability and convenience advantages.
Investor unrest expected as Allergan’s NMDA receptor modulator rapastinel fails in Phase III depression program, coming shortly after J&J’s approval in the class with Spravato.